SP1 and leukemia: INSR is activating PI3K, MAPK, and ERK signaling and has been linked to several tumors including leukemia [79, 80] and PPARG can bind to AP2-ɑ and SP1 and decrease the upregulation effect of AP2-ɑ on INSR in breast cancer [80–83].